First AD

Second AD

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

ZUMA-3: CAR T Therapy for Adult Patients With ALL

OncLive News Network®

Thought leaders in the management of ALL discuss the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy, and lead trial author Bijal Shah, MD, MS, comments on the future application of MRD status. 

The ZUMA-3 Trial: Clinical Endpoints

The Evolving Treatment Landscape for ALL 

Using MRD to Monitor Therapeutic Response in  ALL 

The ZUMA-3 Trial: Study Design and Patient Population

The ZUMA-3 Trial: Efficacy and Safety Results

The Potential Future Impact of CAR T Cell Therapy in Adult ALL